Clinical Trial · NCT02134340

A Safety and Biodistribution Study of [I-124]-CPD-1028 Injection in Solid Tumours

Overview

The purpose of the study is to evaluate the safety and biodistribution of \[I-124\]-CPD-1028 Injection in cancer patients with solid tumours.

Sponsor

Unknown Organization

Phase

Phase 1

Contacts

Eric Burak, PhD (STUDY_DIRECTOR)

ClinicalTrials.gov

Drug / Compound

Isotope(s):

Target(s):

Eligibility

Patients must have adequate organ and marrow function, vital signs and ECG.
Patients must have progressed after at least first-line chemotherapy and have an Eastern Cooperative Oncology Group (ECOG) status of 0, 1 or 2.
All patients must have archival tumour samples available and must have verification of IGF-1R expression.
Females of childbearing potential must not be pregnant and both males and females must use adequate forms of contraception.
1. Age ≥18 years old with life expectancy \> 12 weeks with confirmed metastatic or unresectable malignancy

Patients who are currently taking antithyroid medications and lithium or potassium sparing diuretics.
1. Patients who have had chemotherapy or radiotherapy within 2 weeks prior to entering the study or those who have not recovered from previous treatment.
Patients who have received a therapeutic radiopharmaceutical in the past year or who are currently receiving any other investigational agents.
Subjects with known or suspected allergies or contraindications to the investigational agents and iodine
Previous treatment with IGF-1R inhibitors.